Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 13/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115380 | 0.86 | SLC5A2 (0.58) | SLC5A2SLC5A1CYP11B2LMNAMAPT | |
| SCHEMBL21106982 | 0.86 | SLC5A2 (0.58) | SLC5A2SLC5A1CYP11B2LMNAMAPT | |
| SCHEMBL14406494 | 0.86 | SLC5A2 (0.61) | SLC5A2SLC5A1CYP11B2LMNAMAPT | |
| SCHEMBL12714466 | 0.86 | SLC5A2 (0.58) | SLC5A2SLC5A1CYP11B2LMNAMAPT | |
| SCHEMBL155089 | 0.86 | SLC5A2 (0.45) | SLC5A2SLC5A1MAPTABCB11ADORA3 | |
| SCHEMBL19493642 | 0.84 | SLC5A2 (0.56) | SLC5A2SLC5A1CYP11B2LMNAMAPT | |
| SCHEMBL13278033 | 0.83 | SLC5A2 (0.57) | SLC5A2SLC5A1CYP11B2LMNAMAPT | |
| SCHEMBL152965 | 0.82 | SLC5A2 (0.45) | SLC5A2SLC5A1CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL157268 | 0.81 | SLC5A2 (0.42) | SLC5A2SLC5A1LMNAMAPT | |
| SCHEMBL156337 | 0.81 | SLC5A2 (0.40) | SLC5A2SLC5A1LMNAMAPTABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455374-B1 | Process for the Preparation of Compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-16 | — | — | EP | disclosed |
| EP-2457908-B1 | Process for the Preparation of Compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-9056850-B2 | Process for the preparation of compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-06-16 | — | — | US | disclosed |
| US-9056850-B2 | Process for the preparation of compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-06-16 | — | — | US | disclosed |
| US-9056850-B2 | Process for the preparation of compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-06-16 | — | — | US | disclosed |
| EP-2346888-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-02 | — | — | EP | disclosed |
| EP-2346888-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-02 | — | — | EP | disclosed |
| EP-2457908-A1 | Process for the Preparation of Compounds useful as inhibitors of SGLT | Janssen Pharmaceutica N.V. (BE) | 2012-05-30 | — | — | EP | disclosed |
| EP-2455374-A1 | Process for the Preparation of Compounds useful as inhibitors of SGLT | Janssen Pharmaceutica N.V. (BE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2346888-A2 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Janssen Pharmaceutica, N.V. (BE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010043682-A2 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043682-A2 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885CYP11B2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.